ArticleJournal of virology2022
Deletion of E184L, a Putative DIVA Target from the Pandemic Strain of African Swine Fever Virus, Produces a Reduction in Virulence and Protection against Virulent Challenge.
Article in Journal of virology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
44 citing papers in PubMed, 39 citations in OpenAlex.
- Multiple directed mutagenesis reduces enzymatic activity and antibody recognition of the African Swine Fever Virus E2 ubiquitin-conjugating protein (ASFV-pI215L).Emerging microbes & infections · 2026Article
- The deletion of the EP402R and MGF505/360 genes attenuates a genotype I/II recombinant ASFV but fails to confer complete protection against homologous or genotype II challenge in pigs.Emerging microbes & infections · 2026Article
- Adjuvant-induced macrophage activation compromises BA71ΔCD2-mediated protection against African swine fever virus.NPJ vaccines · 2026Article
- Host-pathogen interactions in African swine fever: From viral entry to systemic disease progression.Cell insight · 2026Review
- Live Attenuated Vaccines for African Swine Fever: Perspectives on Their Use and Strategic Directions.Transboundary and emerging diseases · 2026Review
- African swine fever vaccine ASFV-G-ΔI177L induces solid protection in four-week-old piglets.Scientific reports · 2025Article
- Deletion of the African swine fever virus E120R gene completely attenuates its virulence by enhancing host innate immunity and impairing virus release.Emerging microbes & infections · 2025Article
- Hope and hurdles: unlocking the potential of modified live virus vaccines for African swine fever.Emerging microbes & infections · 2025Review
- An attenuated African swine fever virus with deletions of theJournal of virology · 2025Article
- Advances in African swine fever virus molecular biology and host interactions contributing to new tools for control.Journal of virology · 2025Review
- Article
- The CP123L protein of African swine fever virus is a membrane-associated, palmitoylated protein required for viral replication.Journal of virology · 2025Article
- The Potential of Disabled Infectious Single Cycle (DISC) Virus Platforms for Next Generation African Swine Fever Vaccine Development.Transboundary and emerging diseases · 2025Review
- Pathogenicity and virulence of African swine fever virus.Virulence · 2024Review
- Strategic nucleic acid detection approaches for diagnosing African swine fever (ASF): navigating disease dynamics.Veterinary research · 2024Review
- Towards Safe African Swine Fever Vaccines: TheAnimals : an open access journal from MDPI · 2024Article
- Advancement in the Antigenic Epitopes and Vaccine Adjuvants of African Swine Fever Virus.Pathogens (Basel, Switzerland) · 2024Review
- Viroporin-like activity of the hairpin transmembrane domain of African swine fever virus B169L protein.Journal of virology · 2024Article
- Identification of two novel B cell epitopes on E184L protein of African swine fever virus using monoclonal antibodies.Virus research · 2024Article
- Six adenoviral vectored African swine fever virus genes protect against fatal disease caused by genotype I challenge.Journal of virology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
African swine fever (ASF) is currently causing a major pandemic affecting the swine industry and protein availability from Central Europe to East and South Asia. No commercial vaccines are available, making disease control dependent on the elimination of affected animals. Here, we show that the deletion of the African swine fever virus (ASFV) E184L gene from the highly virulent ASFV Georgia 2010 (ASFV-G) isolate produces a reduction in virus virulence during the infection in swine. Of domestic pigs intramuscularly inoculated with a recombinant virus lacking the E184L gene (ASFV-G-ΔE184L), 40% experienced a significantly (5 days) delayed presentation of clinical disease and, overall, had a 60% rate of survival compared to animals inoculated with the virulent parental ASFV-G. Importantly, all animals surviving ASFV-G-ΔE184L infection developed a strong antibody response and were protected when challenged with ASFV-G. As expected, a pool of sera from ASFV-G-ΔE184L-inoculated animals lacked any detectable antibody response to peptides partially representing the E184L protein, while sera from animals inoculated with an efficacious vaccine candidate, ASFV-G-ΔMGF, strongly recognize the same set of peptides. These results support the potential use of the E184L deletion for the development of vaccines able to differentiate infected from vaccinated animals (DIVA). Therefore, it is shown here that the E184L gene is a novel ASFV determinant of virulence that can potentially be used to increase safety in preexisting vaccine candidates, as well as to provide them with DIVA capabilities. To our knowledge, E184L is the first ASFV gene product experimentally shown to be a functional DIVA antigenic marker.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.